Propecia, a medication that treats male pattern baldness, has been recently linked
with erectile dysfunction, reduced sexual desire, prostate cancer, and
male breast cancer. If you or a loved one is currently taking or have
taken Propecia and have experienced erectile dysfunction, reduced sexual
desire, or have been diagnosed with prostate or male breast cancer, you
should contact our New York City defective drug injury attorneys at Sullivan
& Brill, LLP. Our lawyers are knowledgeable about this drug and the
lawsuits that have been filed against the manufacturer. Your
initial consultation is free of charge, and we work on a contingency fee basis, which means you only pay attorney
fees if we are able to successfully obtain compensation. We understand
the financial hardships you are already enduring, and we want to make
things easier on you.
Propecia, generically known as finasteride, is manufactured by Merck &
Co., Inc. and was approved by the FDA in 1997 for men seeking to reduce
male pattern baldness and for men suffering from enlarged prostates, known
as benign prostatic hypertrophy (BPH). Propecia is a specific type of
5-alpha reductase inhibitor that inhibits the enzyme responsible for regulating
the conversion of testosterone to dihydrotestosterone (DHT). The 5mg version
of Propecia is used to treat enlarged prostate, while the 1mg dose treats
male pattern baldness. Since its release, Propecia has been linked to
a number of very significant side effects.
In March 2011, a study conducted by a professor from George Washington
University and published in the Journal of Sexual Medicine showed that
94% of subjects taking the drug developed low libido, 92% developed erectile
dysfunction and decreased arousal, and 69% developed problems with achieving
orgasm. Merck had warned that a small percentage of Propecia users could
experience erectile dysfunction and decreased libido, but stated that
these symptoms would go away after discontinuing the drug. The George
Washington University study demonstrated that some side effects could
last up to an average of 40 months after the last dose.
On June 9, 2011, the FDA issued a press release warning that men taking
the drug may also face a higher risk of developing high-grade prostate
cancer. The warning was based on the FDA's review of two large randomized
controlled trials, the Prostate Cancer Prevention Trial (PCPT) and the
Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. These
trials showed that Propecia and other medications in the 5-alpha reductase
inhibitor (5-ARI) increased the chances of developing high-grade tumors.
In August 2011, the Canadian Health Agency, Health Canada, reported findings
of male breast cancer in a small number of patients taking the drug. According
to Health Canada, male breast cancer has been reported with both the 1
mg and 5 mg formulations of Propecia, though most have been associated
with the 5mg formulation. Health Canada has advised that men taking Propecia
contact their doctors should they experience breast enlargement, breast
lumps, pain or tenderness, nipple discharge, or any other changes while
taking the drug.
Lawsuits have been filed against Merck & Co., Inc. alleging that the
company failed to adequately warn the public that Propecia could cause
serious and potentially irreversible sexual complications.
Contact us today for a free legal consultation or questions regarding a potential future